Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA population-based clinical trial of irinotecan and carboplatin
Journal of Oncology, 06/15/09
Lau D et al. – Study demonstrates that the population-based design of phase I trial allows optimization of dose intensity and derivation of a population-based maximum tolerated dose (pMTD). The pMTD has been applied in phase II trial of irinotecan and carboplatin in patients with small-cell lung cancer.
Methods- Study describes a population-based design for phase I trials of combining anticancer drugs such as irinotecan and carboplatin
- Intrapatient dose escalation of irinotecan and carboplatin was performed to reach individual dose-limiting toxicity (DLT)
- 50 pts with solid tumors refractory to previous chemotherapy
- The individual toxicity-limiting dose levels were analyzed for normal distribution using the method of Ryan-Joiner
- This was subsequently used to determine a pMTD
- For comparison, a simulation study was performed using the method of modified Fibonacci
- Most common DLTs: neutropenia (58%), thrombocytopenia (16%), and diarrhea (8%)
- Fequency of individual toxicity-limiting dose levels of 50 pts approximated a normal distribution
- Dose levels associated with individual limiting toxicities ranged from level 1 to level 8
- pMTD was determined to be dose level 3 (150mg/m2 for irinotecan and AUC=5 for carboplatin)
- In contrast, the MTD was determined to be dose level 4 (200mg/m2 for irinotecan and AUC 5 for carboplatin) by modified-Fibonacci simulation
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists
Clinical Therapeutics, 10/15/09
Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials
Current Medical Research and Opinion, 10/27/09
Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis
Digestion, 10/15/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Randomized Trial of Doxycycline for Mansonella perstans Infection
New England Journal of Medicine, 10/08/09
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Clinical Cancer Research, 10/19/09
Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09
Sponsor
Article Search
Sponsor